Sponsors (7)
Introduced July 23, 2025 by Kelly Morrison · Last progress July 23, 2025
The bill strengthens newborn‑screening detection, data sharing, research, and family education to speed diagnosis and care, but does so at the cost of increased privacy risks, implementation and budgetary burdens, potential state‑federal tension, and some legal/funding uncertainties.
Nearly all newborns and their families will get faster, more consistent identification and follow-up for treatable conditions because the bill requires standardized near–real-time data linkage, CDC support for better tests and lab practices, and mandatory piloting to accelerate real-world deployment.
Parents and families will receive clearer, literacy‑appropriate educational materials and outreach that improve understanding of newborn screening, follow-up, and available services.
Improved advisory guidance on genetic testing and CDC-authorized development of new screening tests could speed diagnosis and expand detection of treatable heritable disorders.
Parents and infants face increased privacy and civil‑liberty risks because the bill promotes near–real‑time EHR data linkages and easier reuse of dried blood spots without strengthening explicit consent or privacy protections.
Taxpayers, state health departments, and hospitals will likely face substantial administrative and IT costs to implement tailored communications, EHR standardization, data systems, expanded testing, and mandatory pilot programs.
Smaller local programs, community groups, and nonprofits risk losing capacity if higher standards are enforced without additional funding, reducing local service availability and outreach.
Based on analysis of 8 sections of legislative text.
Updates federal newborn screening law to expand education and follow-up duties, strengthen surveillance and lab activities, alter advisory duties, change some funding figures, and classify nonidentified dried blood-spot research as secondary research.
Updates federal newborn screening programs by expanding education and follow-up duties, strengthening surveillance and lab evaluation activities, adjusting advisory committee responsibilities, changing some programmatic funding/authorization language, and clarifying how research on nonidentified newborn dried blood spots is classified for human-subjects review. The bill also converts certain discretionary research program language into mandatory requirements and adds new expectations for data standardization and state program coordination to improve detection, diagnosis, and connections to long-term care. The changes affect federal agencies that run and fund newborn screening and surveillance (including CDC and HHS), state newborn screening programs and public health labs, health care providers and hospitals, researchers using dried blood spots, and parents/families of screened newborns by expanding education, data sharing, and program accountability requirements.